All News ExpreS2ion Biotech Holding AB

Equities

EXPRS2

SE0008348262

Market Closed - Nasdaq Stockholm Other stock markets 08:59:31 20/05/2024 pm IST			5-day change	1st Jan Change
1.364 ^SEK	-3.12%		-8.46%	-35.36%

16/05	ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/04	ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ExpreS2ion Biotech : Interim report for January – March 2024 (Q1)	16/05	PU
ExpreS2ion announces financial results for the first quarter of 2024	16/05	AQ
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
ExpreS2ion to present in spring investor events	15/05	AQ
ExpreS2ion Biotech : Annual report 2023 including Auditor’s report	08/05	PU
ExpreS2ion annual report for 2023 published	08/05	AQ
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)	03/05	AQ
ExpreS2ion announces a rights issue of units of approximately SEK 60 million	03/05	AQ
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS	23/04	AQ
ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023	16/04	AQ
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate	16/04	AQ
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	16/04	CI
ExpreS2ion to present in investor and R&D events in March	15/04	AQ
ExpreS2ion to present in investor and R&D events in March	29/02	AQ
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	21/02	MT
ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine	21/02	AQ
ExpreS2ion announces financial results for the fourth quarter and full-year 2023	08/02	AQ
ExpreS2ion to present in Redeye Fight Cancer event and the Bio Innovation Leaders Summit	22/01	AQ
ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast	12/12	AQ
Pareto Securities publishes research report	04/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News ExpreS2ion Biotech Holding AB

Equities

EXPRS2

SE0008348262

All News

Filters